European Journal of Pharmaceutical Research

European Journal of Pharmaceutical Research (EJPR) is a leading international peer-reviewed academic journal that publishes high quality research and analysis on all aspects of pharmaceutical studies. European Journal of Pharmaceutical Research aims to publish the research related to: Pharmacology: Basic molecular and cell biology, physiological and pathological mechanisms, structural biology for therapeutic target identification, rational drug design, mechanism of drug action, preclinical and... Read More ->

Editor in chief:

Dr. Nicolas ANTON, University of Strasbourg, Faculty of Pharmacy, CNRS 7199 – France

ISSN-e: 2650-7501

Editorial Board
Indexed in
Publication Ethics

Editor-in-Chief:

Dr. Nicolas ANTON
University of Strasbourg, Faculty of Pharmacy, CNRS 7199, Strasbourg, France
nanton@unistra.fr

 

Editorial board:

Dr. Arnaud BEDUNEAU
University of Franche Compté, Faculty of Pharmacy, Besançon, France
arnaud.beduneau@univ-fcomte.fr

Dr. Mohamed ATTIA
Clemson University, Bioengineering – Nanomedicine, U.S.A.
mattia@clemson.edu

Dr. Mayeul COLLOT
University of Strasbourg, CNRS 7021, Strasbourg, France
mayeul.collot@unistra.fr

Dr. Shukai DING
Shaanxi university of science and technology, Materials Institute of Atomic and molecular Science, China
dingshukai@sust.edu.cn

Dr. Delphine CHAN-SENG
Institut Charles Sadron, CNRS UPR 22, Strasbourg, France
Delphine.Chan-Seng@ics-cnrs.unistra.fr

Prof. Thierry F. VANDAMME
University of Strasbourg, Faculty of Pharmacy, CNRS 7199, Strasbourg, France
vandamme@unistra.fr

Dr. Cyril AUGER
INSERM 1260, Faculty of Medicine, Strasbourg, France
cyril.auger@unistra.fr

Prof. Christophe A. SERRA
Institut Charles Sadron, CNRS UPR 22, Strasbourg, France
ca.serra@unistra.fr

Dr. Maryam SHETAB BOUSHEHRI
University of Bonn, Pharmaceutical Institute, Bonn, Germany
maryam.sh47@gmail.com

Dr. Frédérique TEWES
University of Poitiers, INSERM U1070, Poitiers, France
ftewes@univ-poitiers.fr

Dr. Abhijit DATE
Pharmaceutical Sciences at Daniel K. Inouye College of Pharmacy, University of Hawaii Hilo, U.S.A.
dateabhi@hawaii.edu

Dr. Ikram ULLAH KHAN
Government College University Faisalabad, Department of Pharmacy, Pakistan
ikramglt@gmail.com

The abstracting and indexing of this journal is in process. The list of the abstracting and indexing will be given very soon.

Plagiarism Policy

To avoid any kind of plagiarism issue, the authors are advised to use proper citation of the material/content/literature that is being use as a reference in the manuscripts. If the content being used in the manuscript is restricted to copy right in any form for further use according to copy right policy of the source publisher, it is essential to seek the permission from the main source of publisher or author, whichever concern. In case the plagiarism is detected even after the publication of the article in this journal, the publication will be cancelled and the article will be removed from the source of publication (online and print versions) of this journal. The whole responsibility to check the plagiarism and to submit the manuscript without any kind of plagiarism, copy right issue or other related matters is solely on the authors. The Editorial Team of this journal neither will be responsible for any copied material nor any plagiarized content submitted by the authors.

Acknowledgements

Being an author is not enough. There are many people or organizations involved to complete a research project or study. The authors are suggested to acknowledge all those contributors who do not meet the criteria for authorship but helped them by providing financial support, technical help, research material at the labs, general support, language or other writing help.

Declaration by the author(s) 

All the submissions in this journal are considered as original research work. At the last step of the online submission process of manuscript, the author has to submit the declaration. The principal author or the author who is submitting the manuscript on behalf of all the contributing authors must agree the terms and conditions of Publication Ethics which are given below:

  • It is certified that it is original work carried out by the authors and this manuscript in its present form is being submitted with consent of all contributing authors.
  • It is declared that this manuscript is neither published nor under consideration for publication nor under review process in any other journal, proceedings or presentation of conference.
  • It is declared that proper references are cited wherever it was necessary and permissions are taken in case the material is copied or reproduced in part from other source to use as a reference in this study.
  • It is also certified that the submitted manuscript or any of its contributing author is not disqualified by COPE (https://publicationethics.org/).
  • It is also declared that the authors will respect and agreed to abide by the publishing policies of the journal that based on Open Access under Creative Common Copy Right License “Attribution 4.0 International (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/.
  • In case of medical research involving human subjects, research ethics and patient’s informed consent prior to any test, clinical trials, health flow chart, privacy, confidentiality and post-trial provisions according to World Medical Association Declaration of Helsinki (https://www.wma.net/wp-content/uploads/2016/11/DoH-Oct2013-JAMA.pdf).

 

Aims and Scopes

European Journal of Pharmaceutical Research (EJPR) is a leading international peer-reviewed academic journal that publishes high quality research and analysis on all aspects of pharmaceutical studies. European Journal of Pharmaceutical Research aims to publish the research related to:

Pharmacology: Basic molecular and cell biology, physiological and pathological mechanisms, structural biology for therapeutic target identification, rational drug design, mechanism of drug action, preclinical and clinical studies, drug toxicity, pharmacoepidemiology, pharmacological characterization and evaluation, pharmacokinetics related studies, therapeutic drug monitoring, adverse drug reactions, personalized treatment protocols.

Pharmacognosy: Phytochemistry, phytopharmaceuticals, herbal drug research, nutraceuticals, Identification and characterization of natural products for therapeutic purposes, identification of pharmaceutical active molecules, pharmacological active ingredient isolation and purification procedures.

Pharmaceutical chemistry: Synthesis and chemical characterization of pharmaceutically active molecules, structure activity relationships, development and validation of new process for synthesis, drug evaluation, drug stability analysis, computational chemistry and simulation studies.

Pharmaceutics: Development of new dosage forms, formulation studies, evaluation of raw materials, methods and process in pharmaceutical industry and improving drug targeting.

Pharmaceutical technology: Development and application of biopharmaceuticals for therapy, novel and improved methods for production of biopharmaceutical in industry and development of new diagnostic and medical devices. Besides these areas commentaries and communications regarding community pharmacy practices which can influence the regulatory policies and treatment protocols are also welcome to be submitted in the journal.

Instructions for Authors

Before to submit your manuscript in this journal, it is highly important to read the instructions given below and prepare your manuscript according to the given guidelines.

Article types

The author can submit the manuscript in different categories. It depends upon the researcher in which category or which type of research he/she has conducted. EURAASS accepts the following categories of research work for its different journals:

  • Book review
  • Case study
  • Clinical trial
  • Commentary
  • Editorials
  • Fast track
  • Full length article
  • Letter to the editors
  • Methodologies or Methods
  • Review article
  • Short communication
  • Short review
  • Special issue

Double‐blind peer‐review

All the submitted manuscripts are initially examined and reviewed by one of the editors. At this stage, if the paper deemed suitable according to the scope and the guidelines of the journal, the editor may send it to reviewers for review process. If the editor feels that the submitted manuscript is not of high enough quality or not relevant to the journal according to its scope, the editor may rejects it at initial stage. The rejection at initial stage provides the opportunity to the authors to consider their manuscript for another journal. Manuscripts that are agreed to send for review, they are sent out for peer review, usually two to three independent reviewers. Once the reviewers report is received to editor, the final decision will be taken by the editor based on the feedback or review report received from reviewers. The decision of the editor about acceptance or rejection of the manuscript will be considered final.

Tentative Editorial Evaluation Timeline (Tentative)

EURAASS editorial team is highly committed to provide full concentration and importance to every submitted manuscript in this journal. The editorial board and the publishing editor are devoted to complete the whole process (review, editing and publication) in very short time to provide the opportunity to our valuable authors to get the decision about their submission. The authors will receive the acknowledgement at the time of submission of their manuscript. The Editor-in-Chief will make it sure to provide the initial decision within two working days whether the manuscript can be sent for review based on its scope, importance in scientific knowledge and if the authors have prepared and written their manuscript by following the given guidelines. Otherwise it will return back to authors with reason to not accept for review process. If the manuscript is accepted for review process, then it will be sent to at least two reviewers. As most of the reviewers have less time due to their personal schedules and research works, they shall be given plenty of time of 2 to 3 weeks to review the manuscript and send back the report to editor. Once the review report receives, the Editor-in-Chief with consultation of Co-Editor/Associate Editors will make decision whether to accept or reject the manuscript based on the review comments of the reviewers. If the manuscript is accepted for publication, the authors will be given two to three weeks for correction, modifications according to the comments of the reviewers and to resubmit it for final publications. Once the corrected version of the manuscript receives to editorial board, it will be published online and in-print by taking into account if the author has made corrections according to the review report. The editorial team will make it sure that your manuscript may publish within ten weeks from the date of its initial submission however in some cases there may be an exceptional delay to publish the article if the review comments are receive late from the reviewers.

Declaration by the author(s)

All the submissions in EURAASS journals are considered as original research work. Author(s) has/have to submit a declaration while submitting the manuscript online. The declaration states as under: It is certified that it is original work carried out by the authors and this manuscript in its present form is being submitted with consent of all contributing authors.

  • It is declared that I am well aware about the Open Access policy of the journal which is clear that “if this manuscript is accepted for publication, it will be published under the Creative Common Attribution-NonCommercial 4.0 International (CC BY-NC 4.0) license which allow to all persons to download and use it free of cost”.
  • It is declared that this manuscript is neither published nor under consideration for publication nor under review process in any other journal, proceedings or presentation.
  • It is declared that proper references are cited wherever it was necessary and permissions are taken in case the material is copied or reproduced in part from other source to use as a reference in this study.
  • It is affirmed that there is no plagiarism in the manuscript. If any kind of plagiarism is found or detected even after the publication of journal, I and other co-authors will be responsible.
  • It is also certified that the submitted manuscript or any of its contributing author is not disqualified by COPE.
  • It is declared that there is no conflict of interest by submitting or publishing this manuscript in this journal.
  • It is also declared that I/we will/shall respect and agreed to abide by the publishing policies of the journal such as (copy right, open access, interest, publication charges, cancellation of publication if any plagiarism proved even after publication, reprint, ).
  • In case of medical research involving human subjects, research ethics and patient’s informed consent prior to any test, clinical trials, health flow chart, privacy, confidentiality and post-trial provisions according to World Medical Association Declaration of Helsinki.

Plagiarism policy

While submitting your manuscript, you need to accept the “declaration by the author(s)” in which second and third points are related to plagiarism policy. In case of any plagiarism before or after the publication of the manuscript is found, the author(s) will be responsible. Therefore it is advised to use proper citation to avoid any issue of plagiarism in future. In case some material is copied from other’s sources/work/research findings etc. that is restricted to copy right in any form for further use according to copy right policy of the publisher, it is essential to seek the prior permission to use it from the main source of publisher or author, whichever concern. In case the plagiarism is detected even after the publication of the article, the publication will be cancelled and the article will be removed from the journal’s data base. In this case the author(s) will be banned for further submission in EURAASS journals and an alert will be issued about the author’s dishonest and unacceptable practice by using COPE forum.

Open access policy

EURAASS is determined to facilitate the global research community through its Open Access policy. For this purpose it applies the Creative Common Attribution-NonCommercial 4.0 International (CC BY-NC 4.0) license to all kind of publications which are published by EURAASS. Under this license, authors retain ownership of the copyright for their content. However they allow anyone to download, reuse, reprint, remix, redistribute and/or copy the content as long as the original authors and source are cited. You must give appropriate credit, provide a link, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use. All the authors who wish to publish in this journal must agree the Open Access policy of the journal for which their manuscript is accepted for publication. For further understanding and details, you may further read at the following link: https://creativecommons.org/licenses/by-nc/4.0/ or visit the website of Creative Commons at https://creativecommons.org/share-your-work/.

Length of manuscript

There is no page limit for the manuscripts submitted in EURAASS journals. However it is encouraged if the manuscript does not exceed to 15 pages including text, figures, tables and references. The supplementary material supporting to the manuscript can be submitted as a separate file along with the manuscript file. The supplementary material will not be published with the article. Submission of manuscript based on short communication should not exceed more than 6 pages including text, tables, figures and references.

Language

All the journals of EURAASS are published in English. Author should use British English or American English for vocabulary, terminology, grammar and spellings, which must be consistently applied throughout the manuscript. If the English is not the mother language of the author, it is highly encouraged to ensure that the spellings and terminology used in the manuscript are correct before to submission in one of the EURAASS journals. Language errors may cause to delay the review process or may have maximum chances of rejection of the manuscript by the reviewers. Authors whose native language is not English can consult the organizations for editing assistance to overcome the linguistic errors to enhance the chances of acceptance of the article.

Formatting the manuscript for submission

Title page: The title page of the manuscript should include the title of the manuscript, complete names of the authors, their institutional affiliation, email addresses of each author and telephone number of the corresponding author for any necessary communication.

Abstract: For the brief summary of the manuscript, it is necessary to provide an abstract of 200 to 250 words by including the objective/purpose, design/methodology/approach, major results/findings and research limitation/implications.

Key Words: The manuscript should contain 4 to 5 key words just after the abstract.

Text format: Manuscript should be written in in word by using the following designs:

Font style and size: Times Roman font for the text with 10-points. – Alignment of the text should be justified. – If it is necessary to use italic or bold for emphasizing the part of contents. – Insert automatic page number on bottom (center). – For indents to use next paragraph, use tab stops by selecting 0.75 on ruler for the tab stop. – Use proper format for the equations used in the manuscript so that later they may not be distorted.

Tables and figures: All the figures and tables should be numbered properly with suitable captions. The elaboration and labelling of figures should be clear and easy readable and properly printable.

Abbreviations: The author(s) should define all the abbreviation at first mention and thereafter the author can use only the abbreviation in the whole manuscript wherever it is appearing.

Headings: For the headings in your manuscript, follow the table given below:

Style name Brief Description Example
ARTICLE TITLE 16 pt, bold, and left An Example of Title
Author Names 12 pt, bold Abcdefg, H.I
Author Affiliations 10 pt Department of ………….
Abstract 10 pt As given above (justiffied format)
Keywords 10 pt As given above (justiffied format)
HEADING 1 11 PT, BOLD 1. INTRODUCTION
Heading 2 11 pt, bold 1.1 Causes of climate change
Heading 3 11 pt, italic 1.1.1 Emission of CO2
Paragraph 10 pt As abstract
Figure caption 10 pt Figure 1: Map of study area
Table caption 10 pt Table 5: Global population growth from 1901 to 2017.

Footnotes: The authors are advised not to use the footnotes. It is encouraged to use the references in spite of using footnotes.

Acknowledgement

The author(s) should acknowledge the people, institutes, funding agencies or other people who remained involve in any way to complete the research work. If the manuscript is part of a project, please mention the project approval number, date and funding institute for that project.

References

All the literature, figures, tables or other material consulted or taken from other sources must be cited properly. For all sources of literature consulted or to use as a reference, the author(s) is advised to use APA (American Psychological Association) style. As a guideline for the author(s) some examples of this style to use as a reference are given below.

Citing a journal article in print: Author, A. (Publication Year). Article title. Periodical Title, Volume(Issue), pp.-pp. Example: Ho Q.B., Clappier,A., and Blond, N (2014) Fast and optimized methodology to generate road traffic emission inventories and their uncertainties. Journal of CLEAN-Air, Water and Soil, 42(10): 1344-1350.

Citing a journal article found online: Author, A. (Publication Year). Article title. Periodical Title, Volume(Issue), pp.-pp. DOI:XX.XXXXX. Example: Selmi, W., C. Weber, E. Rivière, N. Blond, L. Mehdi, D. Nowak (2016). Air pollution removal by trees in public green spaces in Strasbourg city, France, Urban Forestry & Urban Greening, 17: 192-201, http://dx.doi.org/10.1016/j.ufug.2016.04.010.

Citing a book in print: Author, A. (Year of Publication). Title of work. Publisher City, State: Publisher. Example: Adams, W.M (2009). Green development: environment and sustainability in a developing world. 3rd ed. New York, Routledge.

Citing of an e-book: Author, A. (Year of Publication). Title of work [E-Reader Version]. Retrieved from http://xxxx or DOI:xxxx Example: Santos de Silva, M and Cano, M.I.N (2017) Frontiers in parasitology: Molecular and cellular biology of pathogenic trypanosomatids. Bentham eBook Imprint. Retrieved from https://books.google.fr/books.

Citing a website article with an author: Author, A. (Year, Month Date of Publication). Article title. Retrieved from URL. Example: Rincon, P. (2018, January 10) ‘Serious gap’ in cosmic expansion rate hints at new physics. Retrieved from http://www.bbc.com/news/science-environment-42630399.

Citing a website article without an author: Article title. (Year, Month Date of Publication). Retrieved from URL. Example: Insect declines: new alarm over mayfly is ‘tip of iceberg’, warn experts (2018, 10 January). Retrieved from https://www.theguardian.com.

Citing a magazine article in print: Author, A. (Year, month of Publication).Article title. Magazine Title, Volume(Issue), pp.-pp.

Citing a magazine article found online: Author, A.A. (Year, Month of Publication). Article title. Magazine Title,Volume(Issue), Retrieved from http://xxxx Example: Haeberlein, S.B. (2018, January 4). Why this scientist is hopeful a cure to alzheimer’s disease isn’t far off. Times, 191(1), Retrieved from http://time.com/5087364/scientist-hopeful-cure-to-alzheimers-disease-isnt-far-off/.

Publication charges

Submission of manuscript in all the journals of EURAASS is free of cost. However after the peer-review process, if the manuscript is accepted for publication, there applies a one-time article processing charges on each accepted article. The publication charges are applied for the publication of article in-print and online, to meet the cost of online data base, to secure the data base of published articles, distribution of the published articles, cost of postal services, to support the journal’s handling staff and to fully ensure the free of cost availability of the article online in perpetuity under a Creative Commons license.

The article publication charges are only 135 Euros which are payable only for an accepted manuscript. 

In some exceptional cases if the author is facing difficulty to pay online, the principal author can contact to Editor-in-Chief or Managing Editor (managing-editor@euraass.com) to discuss his/her issue to find the solution of payment. For further details and queries, please feel free to contact the Editor-in-Chief of the journal or Managing Editor at managing-editor@euraass.com.

OPEN ACCESS POLICY Attribution-NonCommercial 4.0 International (CC BY-NC 4.0) https://creativecommons.org/licenses/by-nc/4.0/

EURAASS is determined to facilitate the global research community through its Open Access policy. For this purpose it applies the Creative Common Attribution-NonCommercial 4.0 International (CC BY-NC 4.0) license to all kind of publications which are published by EURAASS. Under this license, authors retain ownership of the copyright for their content. However they allow anyone to download, reuse, reprint, remix, redistribute and/or copy the content as long as the original authors and source are cited. You must give appropriate credit, provide a link, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use. All the authors who wish to publish in this journal must agree the Open Access policy of the journal for which their manuscript is accepted for publication. For further understanding and details, you may further read at the following link:

You are free to:

Share — copy and redistribute the material in any medium or format

Adapt — remix, transform, and build upon the material The licensor cannot revoke these freedoms as long as you follow the license terms. The licensor cannot revoke these freedoms as long as you follow the license terms. Under the following terms:

Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

Non-Commercial — You may not use the material for commercial purposes.

No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.

Notices: You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation. No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material. For further understanding and details, you may further read at the following link: https://creativecommons.org/licenses/by-nc/4.0/ or visit the website of Creative Commons at https://creativecommons.org/share-your-work/.

The details of this section will be provided soon.

No article in this section at present.

Issue 1 
Editorial, Eur. J. Pharm. Res. 2019, Vol. 1, Issue 1, p. 1.
Inaugural Issue Editorial Note
Nicolas Anton
University of Strasbourg, CNRS, CAMB UMR 7199, F-67000 Strasbourg, France
Research Article, Eur. J. Pharm. Res. 2019, Vol. 1, Issue 1, p. 2-11.
Use of leucine to improve aerodynamic properties of ciprofloxacin-loaded maltose microparticles for inhalation
Barbara Lamy,a Dolores Remedios Serrano,b,c Peter O’Connell,b William Couet,a,d Sandrine Marchand,a,d Anne Marie Healy,b Frederic Tewes a,*
a INSERM, U1070, UFR de Médecine Pharmacie, Université de Poitiers, 1 rue Georges Bonnet, TSA 51106, 86073 Poitiers Cedex 9, France
b Synthesis and Solid State Pharmaceutical Centre, School of Pharmacy and Pharmaceutical Sciences, Trinity College Dublin, Panoz Institute, Dublin 2, Ireland
c Departamento de Farmacia y Tecnologia Farmaceutica, Facultad de Farmacia, Universidad Complutense de Madrid, Plaza Ramon y Cajal s/n, Madrid, 28040, Spain
d Laboratoire de Toxicologie-Pharmacocinétique, CHU of Poitiers, 2 rue de la Milétrie, 86000 Poitiers, France
Research Article, Eur. J. Pharm. Res. 2019, Vol. 1, Issue 1, p. 12-19.
Single-step and low-energy method to prepare solid lipid nanoparticles and nanostructured lipid carriers using biocompatible solvents
Abhijit A. Date,a,b Mangal S. Nagarsenker,a,*
a Department of Pharmaceutics, Bombay College of Pharmacy, Kalina, Santacruz (E), Mumbai 400098, Maharashtra, India
b Department of Pharmaceutical Sciences, The Daniel K. Inouye College of Pharmacy, University of Hawaii at Hilo 200 W. Kawili Street, Hilo, Hawaii 96720, USA
Research Article, Eur. J. Pharm. Res. 2019, Vol. 1, Issue 1, p. 20-26.
A focus of the nanoprecipitation by solvent displacement: example of poly(MAOTIB) intended to in vivo applications
Justine Wallyn, Thierry Vandamme, Nicolas Anton*
University of Strasbourg, CNRS, CAMB UMR 7199, F-67000 Strasbourg, France
Research Article, Eur. J. Pharm. Res. 2019, Vol. 1, Issue 1, p. 27-36.
Spontaneous nano-emulsification with tailor-made amphiphilic polymers and related monomers
Asad Ur Rehman,a,b Mayeul Collot,c Andrey S. Klymchenko,c Salman Akram,a Bilal Mustafa,a Thierry Vandamme,a Nicolas Anton a,*
a University of Strasbourg, CNRS, CAMB UMR 7199, F-67000 Strasbourg, France
b Bahauddin Zakariya University (BZU) Multan, Pakistan
c University of Strasbourg, CNRS, LBP UMR 7021, F-67000 Strasbourg, France